Summary of the Conference Call for Sihuan Pharmaceutical Company Overview - **Company**: Sihuan Pharmaceutical - **Industry**: Pharmaceutical and Aesthetic Medicine Key Points Financial Performance and Projections - Sihuan Pharmaceutical is expected to turn profitable in 2025, with projected earnings between 150 million to 250 million RMB, reversing previous losses due to R&D investments in innovative drugs and the impact of generic drug procurement [2][5] - The company anticipates entering a product expansion and distribution phase in 2026 and 2027, which is expected to further enhance performance [2][4] - The aesthetic medicine segment is projected to generate nearly 1.4 billion RMB in revenue by 2025, driven by strong sales of the botulinum toxin product, Letibotulinum, expected to reach around 1 billion RMB, and the Sephora Youth Needle, estimated at 200 million RMB [2][6] Product Pipeline and Market Position - Sihuan Pharmaceutical has a robust pipeline in the aesthetic medicine sector with nearly 60 products, showcasing strong R&D capabilities and significant channel advantages [2][4] - Letibotulinum is rapidly penetrating approximately 8,000 aesthetic institutions, with new products like the Youth Needle and Composite Water Light Needle also performing well [2][4] - For 2026, Letibotulinum is expected to maintain a growth rate of over 20%, while new products are projected to achieve sales of 400-500 million RMB [2][6] Innovative Drug Business - The innovative drug segment is expected to significantly reduce losses in 2026, with anticipated annual revenue exceeding 500 million RMB, and a potential break-even point in 2027 [2][7] - Core products such as CDK 4/6 are entering a commercialization acceleration phase, supported by the listing of the subsidiary, Xuanzhu [2][7] Market Valuation and Investment Potential - Current market capitalization of Sihuan Pharmaceutical is 14.1 billion RMB, with earnings forecasts of 710 million and 930 million RMB for 2026 and 2027, respectively, leading to P/E ratios of 19.8 and 15.2 [3][7] - The valuation is considered low relative to growth potential, with a reasonable valuation estimated at 22-25 times P/E, suggesting a target market cap of 21 billion RMB, indicating a potential upside of approximately 50% [3][7] Market Conditions and Strategic Outlook - Recent surveys indicate a stabilization in demand within the aesthetic medicine industry, with some institutions experiencing a shift from declining to positive growth [4] - Improved market liquidity compared to the previous year and increased attention from core institutional investors are expected to bolster the company's market position [5] Additional Insights - The aesthetic medicine segment's revenue for 2025 is expected to be around 1.4 billion RMB, with the generic and innovative drug segments contributing an estimated 1-1.1 billion RMB [6] - The company is poised for significant growth, with a focus on leveraging its product pipeline and market conditions to enhance shareholder value [5][6]

Summary of the Conference Call Industry Overview - The focus is on the medical aesthetics (医美) industry, which is showing signs of demand stabilization and potential growth for the company’s products in 2025 and beyond [1][2]. Key Insights 1. **Demand Stabilization**: Recent surveys in East China indicate a recovery in customer traffic and retail prices after a challenging period from 2022 to 2024, with double-digit growth in customer traffic reported by major institutions [1]. 2. **Retail Price Stability**: Retail prices for established products are stabilizing due to consistent labor and marketing costs, contributing to an upward trend in customer spending [2]. 3. **Upgrading Consumer Behavior**: There is a noticeable trend of existing customers upgrading their consumption, leading to higher average transaction values [2]. Product Segmentation 1. **Injection Fillers**: Hyaluronic acid products face pressure, but the "童颜针" (youthful needle) is expected to see significant growth in 2025 due to more mid-range manufacturers entering the market, with an estimated increase of 15-20% in sales volume [3]. 2. **Collagen Products**: 2025 is projected to be a year of accelerated penetration for collagen products, with an expected factory growth rate of over 20%, although retail prices may face pressure [3]. 3. **Essential Products**: Water-light products remain a necessity, with composite hyaluronic acid products continuing to show resilience, supported by the growth of "童颜水光" and collagen water-light products [3]. 4. **Botulinum Toxin**: This is the second-largest injection category, currently experiencing high single-digit to low double-digit growth in industry sales volume, with growth momentum expected to continue for several years [3]. Company Product Portfolio - Current core products include: - Botulinum toxin "乐提葆" - "斯弗妍" youthful needle - Composite energy product "冷妍" - "铂安润" hyaluronic acid - "黑曜双波" golden microneedle - Future products in development include injectable collagen, silk protein, and PDRN salmon needle [3]. Financial Projections 1. **Profitability Outlook**: The company anticipates a turnaround from loss to profit, estimating a performance of around CNY 200 million in 2025, with a reasonable range between CNY 150 million to CNY 250 million [3]. 2. **Operational Data**: The operational data for various medical aesthetic products is expected to improve, enhancing the reliability of guidance for 2025 and 2027 [3]. 3. **Valuation and Market Potential**: The valuation of the innovative subsidiaries "轩竹" and "惠升" is projected at CNY 4-5 billion, with the generics business expected to generate CNY 1-2 billion in profits. The medical aesthetics segment is projected to achieve CNY 700 million in revenue, warranting a valuation of 25 times [3]. 4. **Future Growth Potential**: The company anticipates a 50% growth potential within the year, with projected profits of CNY 200 million, CNY 790 million, and CNY 900 million for the years 2025, 2026, and 2027 respectively, against a current market capitalization of CNY 12.8 billion, corresponding to PE ratios of 64, 19.7, and 14.2x [3].

Core Insights - The approval of "Dongyan," a hyaluronic acid compound solution, marks a significant breakthrough for the company in the medical aesthetics sector, being the first product in China to include L-carnosine for facial skin improvement [1][4][9] - The product's launch aligns with the rapid growth of the water light needle market, which is projected to reach $1.8 billion globally by 2025 and $4.5 billion in China by 2025, with a CAGR of 21.5% [4][14] Product Overview - "Dongyan" is designed to temporarily improve skin dryness and dullness, ensuring compliance and efficacy through a professional injection model [4][7] - The product features a composite formula that includes key ingredients such as hyaluronic acid, L-carnosine, vitamin B2, and essential amino acids, targeting comprehensive skin management [6][9] Market Positioning - The launch of "Dongyan" fills a gap in the market for compliant facial water light needles containing L-carnosine, which has been absent in China [5][9] - The product's positioning as a comprehensive skin improvement solution caters to the increasing demand for advanced skin health management, particularly among women over 30 [9][14] Strategic Development - The approval of "Dongyan" is part of the company's dual-engine strategy in the medical aesthetics field, complementing existing products like "Tongyan Needle" and "Shaonian Needle" [10][11] - The company has established a robust sales network covering over 6,800 medical aesthetic institutions across more than 370 cities in China, enhancing its market penetration capabilities [11][15] Financial Performance - The medical aesthetics division has shown significant growth, with a reported 85% year-on-year increase in revenue for the first half of 2025, surpassing traditional business revenue contributions [13][14] - The company is expected to continue its positive financial trajectory, supported by the launch of "Dongyan" and ongoing product development in the medical aesthetics sector [12][15]

Summary of the Medical Aesthetics Industry Conference Call Industry Overview - The Chinese medical aesthetics market has a penetration rate of only about 4%, significantly lower than South Korea's 20%, indicating substantial growth potential [2][4] - The market is still in its early stages, with a lack of standardization and a mix of formal and informal institutions [2][4] Key Insights and Arguments - The rise of "light medical aesthetics" is seen as a future direction due to its lower entry barriers and ease of replication, with service frequency increasing from 30% to 70% post-pandemic, and an expected market size of 140 billion RMB [1][4] - New Oxygen's pre-discount model may disrupt traditional institutions, which face high customer acquisition costs and intense price competition [1][4] - New Oxygen has optimized its single-store model, increasing traditional store profit margins from less than 5% to 15% by reducing customer acquisition costs and adopting a light medical aesthetics small store model [1][6][9] Company Strategies - New Oxygen is implementing a simulated chain model that minimizes reliance on doctor IP, establishing a centralized platform for marketing, product development, and supply chain management [9] - The company plans to increase its store count to over 50 by the end of the year and is opening up franchising opportunities to rapidly replicate its light asset model [9] - New Oxygen has invested over 1 billion RMB in upstream supply chain integration, with plans to launch more proprietary products [10] Market Dynamics - The medical aesthetics industry is shifting towards a volume-based model, focusing on bulk sales and affordability through standardized operations and quality service to enhance customer retention [3][11] - The average customer acquisition cost in the industry is around 2000 RMB, with traditional institutions facing high operational costs due to a lack of standardization and high marketing expenses [5][6] Competitive Landscape - Four Ring Pharmaceutical is expected to contribute new revenue streams with products like the "Youthful Needle" and "Girl Needle," targeting a sales goal of 1 billion RMB for its botulinum toxin product [3][13] - Kedi has launched a finasteride spray, anticipating peak sales of at least 1 billion RMB, enhancing its competitive position in the hair loss market [14] - Huadong Pharmaceutical has introduced high-end hyaluronic acid products, with expectations of significant sales growth [15] Future Outlook - The light medical aesthetics market in China is projected to accommodate over a thousand stores, with potential revenues of 40 billion RMB and profits of 6 billion RMB if the market penetrates effectively [12] - The overall sentiment in the medical aesthetics sector is improving, with increased attention and potential for further developments in the third quarter of 2025 [19]